

ACCESS CHINA

ACCESS CHINA Forum 2021 Winter Partnering Event

January 4th–30th, 2021 (online)

**30 KEYNOTE
SPEECHES**

**100 COMPANY
ROADSHOWS**

**500+ 1X1
MEETINGS**

**1000+
PARTICIPANTS**

The Largest Online Corporate Access Event Between China And Western Biopharma Industry



Invitation

We cordially invite you to join our **“ACCESS CHINA Forum @ JPM WEEK 2021”** to be held online on *January 4th-30th*, 2021. This conference is the largest CHINA corporate access event during JPM WEEK. We expect to host 100 Company Presentations, 30 Keynote Speeches, 1000+ Participants, and 500+ 1x1 meetings during the 4-week event.

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.

Company roadshows are divided into nine different therapeutical sessions and three special sessions:

- Oncology (3 sessions)
- Ophthalmology / Orthopedics
- Material / Platform Technology
- IVD / Medical Devices
- Autoimmune Disease
- **Israel Healthcare Showcase**
- **MNC Track**
- CNS / Cardiovascular
- Cell Therapy / Rare Disease
- Genitourinary / Gynecology / Pediatric / GI
- Dermatology / Respiratory / Infectious Disease
- **Swiss Innovation Day**

We look forward to welcoming you at our Winter event in January!

Sincerely,

ACCESS CHINA Forum Organizing Committee



About ACCESS CHINA Forum

ACCESS CHINA Forum is the largest corporate access event between China and Western biopharma industry to facilitate financing and licensing transactions. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. The events offer companies online corporate access through our proprietary platform, which covers 2,000+ BD directors and executives from Chinese and global biopharma, healthcare, and investment firms.



Event Highlights

ACCESS CHINA Winter Forum will last for three weeks starting from January 4th including more than 30 keynote speakers from China & global biopharma industry, 100+ company presentations from North America, Europe, China and rest of Asia. We expect more than 1000 participants globally. ACCESS CHINA Winter Forum will offer 1x1 meetings system for our clients and investors.

3-Week ACCESS CHINA Forum Roadshow schedule

Pre-JPM Week	JPM Week	Post-JPM Week
Jan. 4 th - 8 th	Jan. 11 th - 15 th	Jan. 18 th - 22 nd
<ul style="list-style-type: none"> ■ Keynote Speeches ■ Company Roadshows in Oncology (3sessions), CNS / Cardiovascular / Ophthalmology / Orthopedics 	<ul style="list-style-type: none"> ■ Keynote Speeches ■ Israel Healthcare Showcase ■ Company Roadshows in Cell Therapy / Rare Disease / Material / Platform Technology / Genitourinary / Gynecology / Pediatric / GI / IVD/Medical Devices. 	<ul style="list-style-type: none"> ■ Swiss Innovation Day ■ MNCs Roadshow and other company Roadshows Oncology / Dermatology / Respiratory / Infectious Disease / Autoimmune Disease

EVENT HIGHLIGHTS

100 Company Presentations: 70 Global Biopharma , 30 Chinese Biopharma Companies.

30+ Keynote Speeches: Policy & Regulation, Industry Trend and Landscape, Transactions, Innovation, etc.

1000+ Participants: China Biotech, Pharma, Financial Investors; Global Investors and Biopharma

500+ 1x1 meetings: 1x1 System for YAFO Clients and Investors

Other Features: Swiss Innovation Day and Israel Healthcare Showcase



Agenda

	Monday	Tuesday	Wednesday	Thursday	Friday
Jan. 4 th - 8 th	Opening Speech	Oncology1	CNS / Cardiovascular	Ophthalmology / Orthopedics	Oncology2
Jan. 11 th - 15 th	Cell Therapy/Rare Disease	Israel Healthcare Showcase	Material/Platform Technology	Genitourinary/ Gynecology / Pediatric/GI	IVD/Medical Devices
Jan. 18 th - 21 nd	Swiss Innovation Day	MNCs/Big Pharmas	Dermatology / Respiratory / Infectious Disease	Oncology / Autoimmune disease	
Jan. 25 th - 30 th	1x1 Partnering week!				

* The 1X1 Meeting system is fully open for Chinese investors and pharmas to register and limited to YAFO Clients for overseas companies.



Confirmed Presenting Companies (China)

 Servier 施维雅	 MSD 默沙东	 Bayer 拜耳	 BD	 Abbott 雅培
 Merck Serono 默克雪兰诺	 Roche Diagnostics 罗氏诊断	 Shanghai Pharma 上海医药	 Huadong Medicine 华东医药	 Fosun Pharma 复星医药
 Jemincare 济民可信	 Grand Pharma 远大医药	 Salubris 信立泰	 Tasly 天士力	 Yangtze River 扬子江药业
 Alphamab 康宁杰瑞	 CANbridge 北海康成	 GeneSci Pharma 金赛药业	 SciClone 赛生药业	 Cstone 基石药业
 Sperogenix 曙方医药	 Reistone 瑞石生物	 Carephar 柯菲平	 Ark Biosciences 爱科百发	 OnQuality Pharma 岸阔医药
 Triastek 三迭纪医药	 IASO 驯鹿医疗	 YZY Biopharma 友芝友生物	 Hinova Pharma 海创药业	 AnHeart Therapeutics 葆元生物
 Epimab 岸边生物	 HuiGene 辉大基因	 Gaush 高视	 SinoTau 先通医药	 KONEE 康膝生物
 Beijing Konruns 康辰药业	 Neurofront 神领医药	 Longbio 隆博泰药业	 Bicazer 比卡生物	 Wuhan Langlay 朗来医药

ACCESS CHINA FORUM @ JPM WEEK 2021									
WEEK 1									
星期一（1月4号） Monday, Jan. 4		星期二（1月5号） Tuesday, Jan. 5		星期三（1月6号） Wednesday, Jan. 6		星期四（1月7号） Thursday, Jan. 7		星期五（1月8号） Friday, Jan. 8	
开幕演讲 Opening Speech		肿瘤 1 Oncology 1		神经 / 心脑血管 CNS/Cardiovascular		眼科 / 骨科 Ophthalmology / Orthopedics		肿瘤 2 Oncology 2	
9:00-9:15	Opening Speech & China Biotech Innovation Jeffrey Zhang, Chair (CHBD)	9:00-9:30	Key trends in China biotech BD Andy Fu, VP of BD and Corporate Strategy (Cstone)	9:00-9:30	Disruptive approach to treat CNS diseases via gut-brain axis: autism, a case study David H Donabedian, Co-founder & CEO (Axial Therapeutics)	9:00-9:20	Clinical Transformation of Cartilage 3D BioPrinting Huimin Chen, Founder&CEO (SinoBioPrint)	9:00-9:20	Developing effective cross border partnerships- Building global biotechnology success story. Vishal Doshi, CEO (AUM Biosciences)
9:15-9:30	Cross-border Licensing Annual review Sean Jiang, CEO (YAFO Capital)	9:30-9:50	Grand Pharma Ke Wang (BD Head)	9:30-9:50	Expanding the Frontiers of Neuroscience in China June Yan, CEO (Neurofront)	9:20-9:40	Spineology (Management)	9:20-9:40	YZY Biopharma Yiou Wang (VP)
9:30-10:00	From pipeline to topline, from China to the world Jiaxi Xu, Chief Pharmaceutical Analyst (Industrial Securities)	9:50-10:10	Tactical Tx. Rashida Karmali (CEO&President)	9:50-10:10	Salubris Bio Sam Murphy (CEO)	9:40-10:00	Articulate Labs Josh Rabinowitz (Founder&CEO)	9:40-10:00	BerGenBio Richard Godfrey (CEO)
10:00-10:30	Bio century commercial section- the evolution of china pharma market Tina Hou, Global Partner (Mckinsey)	10:10-10:30	AnHeart Therapeutics Akira Liu (BD Director)	10:10-10:30	Neurogenesis Tal Gilat (CEO)	10:00-10:20	Alimera Sciences Rick Eiswirth (President and CEO)	10:00-10:20	Hinova Pharma Xinghai Li (CSO)
10:30-10:50	Global Transaction Experience - MNC Perspective Cynthia Wang, BD&Licensing Director (Servier)	10:30-10:50	Constellation Pharma Michaela Levin (BD Director)	10:30-10:50	Jixing Pharma (Management)	10:20-10:40	Konee Jianmo Li (CEO)	10:20-10:40	Cerecor (Management)
10:50-11:10	Japan Market Opportunity for Chinese Pharmas Steve Engen, Founder & President (Renexes)	10:50-11:10	SciClone Pharma Xiaoning Guo (VP, R&D and CMO)	10:50-11:10	Huadong Medicine Zigen Wang (BD Director)	10:40-11:00	Gaush Yingqi Xu (Project Manager)	10:40-11:00	Epimab Jason Tang (BD Director)
11:10-11:30	Investment Strategy for the Pharmaceutical Industry: Innovation + Import Substitution Lead the Great Era of Pharmaceuticals Xiangyang Du, Chief Pharmaceutical Analyst (South West Securities)	11:10-11:30	Tasly Ling Tong (BD Director)	11:10-11:30	Oryzon Genomics Carlos Buesa (CEO)	11:00-11:20	Crystal Genomics Steven Kim (Executive Managing Director Head of Business Development)	11:00-11:20	Onquality Rx Michael McCullar (CEO)
		11:30-11:50	Alphamab Ting Xu (Chairman & CEO)	11:30-11:50	Newron Pharma Stefan Weber (CEO)	11:20-11:40	iVis Tech Giuseppe d'Ippolito (CEO)	11:20-11:40	Sinotau (Management)
		11:50-12:10	PDC Line Pharma Eric Halioua (CEO)	11:50-12:10	SOM Biotech Raul Insa (CEO)	11:40-12:00	Oxurion Patrik De Haes (CEO)	11:40-12:00	ISA Pharma Anton Mat (BD Director)
				12:10-12:30	Achieve LS (Management)			12:00-12:20	Bicazer Yingting Xu (CEO)

WEEK 2					
星期一（1月11号） Monday, Jan. 11		星期二（1月12号） Tuesday, Jan. 12		星期三（1月13号） Wednesday, Jan. 13	
细胞疗法 / 罕见病 Cell Therapy / Rare Disease		以色列医疗创新论坛 Israel Healthcare Showcase		泌尿生殖 / 妇科/消化内分泌 Genitourinary / Gynecology / Pediatric / Digestive System	
		材料 / 平台技术 Material / Platform Technology		体外诊断 / 医疗器械 IVD/Medical Device	
9:00-9:20	Targazyme Lynnet Koh (CEO)	9:00-9:20 Fireside Chat - What are SPACs and how can be used by biotech companies as alternative to IPOs. Chardan, Management (SPAC Trends)	9:00-9:20 IP Structure in Research Collaborations Julian Thurston, Founder&CEO (Theobald Associates)	9:00-9:20 Pelvital (Management)	9:00-9:20 Booming biologics: business and investment impact on Med tech Jimmy Jin, Senior Director of BD (Becton Dickinson & Company China)
9:20-9:40	Innovative Opportunities and Challenges of Orphan Drugs in China James Xue, Chairman & CEO (CANbridge)	9:20-9:40 Fireside Chat - What are SPACs and how can be used by biotech companies as alternative to IPOs. Chardan, Management (SPAC Trends)	9:20-9:40 Dyadic Ping Rawson (CFO)	9:20-9:40 GeneScience Pharma (Management)	9:20-9:40 China IVD Industry Landscape Hao Wu, APAC BD Head (Roche Diagnostics)
9:40-10:00	Cell therapy industry and outlook Wenjun Sun, SVP BD (JW Therapeutics)	9:40-10:00 Flometrica Puyang Liu (COO)	9:40-10:00 BioAffinity Technologies Maria Zannes (CEO&President)	9:40-10:00 Italfarmaco Laura Sala (Head of Out-Licensing)	9:40-10:00 JJXH Zongjian Huang (COO)
10:00-10:20	Sperogenix Therapeutics Alan YAN (Co-founder, Chairman, CEO)	10:00-10:20 KAHR Bio Yaron Pereg (CEO)	10:00-10:20 Plasmology4 (Management)	10:00-10:20 Gedeo Biotech Annette Safholm (CEO)	10:00-10:20 PharmGenomics Philipp Freese (CEO)
10:20-10:40	IASO Maxwell Wang (CMO)	10:20-10:40 AsMedic Arie Huber (CEO)	10:20-10:40 Triastek Xiaoling Li (CSO & Co-founder)	10:20-10:40 Seroba Life Sciences (Management)	10:20-10:40 Atlantic Therapeutics Susan Trent (CEO)
10:40-11:00	HuiGene Therapeutics Robin Zhang (Vice President)	10:40-11:00 Kamada Amir London (CEO)	10:40-11:00 Immunwork Tse-wen Chang (CEO&President)	10:40-11:00 AptamiR Therapeutics (Management)	10:40-11:00 Anvajo Stefan Fraedrich (CEO)
11:00-11:20	Neurophth Alvin Luk (CEO)	11:00-11:20 Vvital Biomed Nir Golan (CEO & Co-founder)	11:00-11:20 Ninevah Marc Ramis Castelltort (CEO)	11:00-11:20 Diamedica Tx. (Management)	11:00-11:20 Defymed Richard Bouaoun (Chief Operating Officer)
11:20-11:40	Beijing Konruns (Management)	11:20-11:40 BiomX Jonathan Solomon (CEO)	11:20-11:40 Molzym Gabriel Tirouflet (CEO)	11:20-11:40 Carephar Su Mei (CEO)	11:20-11:40 Spinthera (Management)
11:40-12:00	AC Immune (Management)	11:40-12:00 -	11:40-12:00 Neuromodtronic Karl Schweitzer (CEO)	11:40-12:00 -	11:40-12:00 -

WEEK 3							
星期一（1月18号）		星期二（1月19号）		星期三（1月20号）		星期四（1月21号）	
Monday, Jan. 18		Tuesday, Jan. 19		Wednesday, Jan. 20		Thursday, Jan. 21	
瑞士生物医药论坛		跨国及大药企		皮肤 / 呼吸 / 传染科		肿瘤/自身免疫	
Swiss Innovation Day		MNC & Big Pharma		Dermatology / Respiratory / Infectious Disease		Oncology/Autoimmune Disease	
15:00-15:20	Prescient Therapeutics Steven Yatomi-Clarke (CEO)	9:00-9:20	Bayer Betty Huang (BD Director)	9:00-9:20	Bellerophon Fabian Tenenbaum (CEO)	9:00-9:20	Solasia (Management)
15:20-15:40	Quercis Pharma Ilias Laber (CEO)	9:20-9:40	Abbott (Management)	9:20-9:40	Reistone Biopharma Yufeng Wang (Senior Director of BD)	9:20-9:40	Createrna Science and Technology Yao Xu (BD Director)
15:40-16:00	Volumina Medical Amelie Beduer (CEO)	9:40-10:00	MSD Luna Ji (Director of Search and Evaluation in the Pacific BD&L Hub, MSD)	9:40-10:00	Longbiotech Shuxin Li (Founder,Chairman&CEO)	9:40-10:00	Delta-Fly Pharma (Management)
16:00-16:20	Swiss Biotech Innovation Michael Alforfer, CEO (Swiss Biotech Association)	10:00-10:20	Merck Serono Michael Wang (Director of Business Development)	10:00-10:20	Ark Biosciences Jim Wu (CEO)	10:00-10:20	Sotio (Management)
16:20-16:40	China & Swiss Healthcare Transaction Review Sean Jiang, CEO (YAFO Capital)	10:20-10:40	Keynote Sppech Mingbo Wang, Senior Director of Business Development and Strategy Planning (Ipsen)	10:20-10:40	Sterna Christian Pangratz (CEO)	10:20-10:40	Catalym Manfred Rüdiger (CEO)
16:40-17:00	-	10:40-11:00	Yangtze River Yan Chen (BDM)	10:40-11:00	Mereo Donald Coppen (BD Director)	10:40-11:00	Inflection Biosciences Darren Cunningham (CEO)
17:00-17:20	-	11:00-11:20	Fosun Pharma Anjiang Liu (Senior Advisor/Deputy General Manager)	11:00-11:20	Bluesky Thoms Muster (CEO)	11:00-11:20	Erkim Cem Zorlular (CEO)
17:20-17:40	-	11:20-11:40	Shanghai Pharma Yifeng Jin (BD Senior Manager)	11:20-11:40	SolasCure Celia Harrison (BD Director)	11:20-11:40	Glycotope Patrik Kehler (Scientific & BD Senior Director)
17:40-18:00	-	11:40-12:00	Jemincare (Management)	11:40-12:00	-	11:40-12:00	Sinocelltech Group

Keynote Speakers Confirmed



Opening Speech & China Biotech Innovation



Jeffrey Zhang
Summit Chair, CHBD

Founder of PROMED; Former Vice President of Wuxi AppTec; Successively served as the head of new business development of Pfizer China, director of Johnson & Johnson China's strategic market;

Cross-border Licensing Annual review



Sean Jiang
CFA & CEO & Founder
YAFO Capital

20+ years Wall Street banking & investment experience with Roth Capital, Xiangcai Securities, etc.. Former China GM of ISI Group (Evercore).

Japan Market Opportunity for Chinese Pharmas



Steve Engen
Founder&President, Renexes LLC

20+ years of Japanese and American pharmaceutical industry experience, brought over dozen US pharmaceutical products to the Japanese market.

Bio-century Commercial section- the evolution of china pharma market



Tina Hou
Global Partner, Mckinsey

Tina leads the new-product-launch work in McKinsey's Pharmaceutical & Medical Products Practice in China and has extensive experience in launch excellence issues.

Global Transaction Experience - MNC Perspective



Cynthia Wang
BD Head, Servier China

Cynthia brings with her over 19 years of Healthcare/pharmaceutical industrial experience in China. Cynthia worked as Senior BD manager for Pfizer in Vaccine BD global M&A projects and managing full TAs of out-licensing BD activities

Swiss Biotech Innovation



Michael Altorfer
CEO, Swiss Biotech Association

Dr. Michael Altorfer has more than 20 years of experience in the life science industry comprising both big pharma and smaller biotech organizations.

Booming biologics: business and investment impact on Med tech



Jimmy Jin
Senior Director of BD
Becton Dickinson & Company China

Jimmy Jin is leading business development for BD China. Prior to joining BD, he has worked as director of business development in Thermo Fisher China and a senior consultant in Bain & Company. He and his team have completed 20+ investment and collaboration projects in the sector of medical device, IVD, bio-tech, and analytical instrument.

From pipeline to topline, from China to the world.



Jiayi Xu
Chief Analyst, Industrial Securities

Dr. Xu was graduated from School of Life Sciences of Fudan University. He has rich research experience in pharma and insurance institutions. He led the team to win the No. 1 Best Analyst of New Wealth.

Keynote Speakers Confirmed



Cell therapy industry and outlook



Wenjun Sun
SVP BD, JW Therapeutics

Wen-jun Sun has over 20 years of broad leadership experience at Merck (MSD) at the US global headquarter and MSD China, in R&D, Manufacturing, Finance, Business development and partnership management.

China Biotech, Lovely Bubble, Lovely Cream



Sam Ma
Co-Founder, CHBD

Sam has over 25 years experience in China, EU, US, Japan and India Life science industry, including AIDEA Pharma Co. Ltd, Urihk Pharma, GSK China and Global and Eisai China.

Investment Strategy for the Pharmaceutical Industry: Innovation + Import Substitution Lead the Great Era of Pharmaceuticals



Xiangyang Du
Chief Analyst, the pharmaceutical industry, South West Securities

Mr. Du was a doctoral candidate of the Chinese Academy of Sciences, received Master of Science degree from the Chinese Academy of Sciences. He has 6-year research experience in the pharmaceutical industry.

Pharma BD in China



Kui Wang,
Secretary General, CHBD

Mr. Wang has rich experience in pharma Business Development for more than 20 years with a record more than 50 M&A and licensing transactions. He worked in Saiya Consulting, Eisai Pharma, Leo Pharma, and Eddingpharm.

IP Structure in Research Collaborations



Julian Thurston
CEO&Founder
Crescendo Enterprises LLC

Julian Thurston has been "top ranked" for commercial lifesciences since the leading legal directories (such as Chambers, Legal 500 and PLC) began covering the sector, and in Chambers Global has been ranked one of the top 10 lawyers globally for commercial lifesciences for over 10 years.

Clinical Transformation of Cartilage 3D BioPrinting



Huimin Chen
Founder&CEO, SinoBioPrint

Dr. Huimin Chen is the founder and CEO of Huaxia SinoBioPrint (Shanghai) Biotech Ltd. and Jiangyin StemEasy Biotech Ltd. He focuses on the research, development and clinical application of cartilage 3D bioprinted and stem cell regenerative medicine in orthopedics, sports medicine and plastic surgery.

Expanding the Frontiers of Neuroscience in China



June Yan
CEO, Neurofront Therapeutics

20 years of experience working in the pharma industry in a variety of markets including the United States, China and Asia. June had multiple key leadership roles in pharma MNCs and biotech companies including 17 years in Eli Lilly, Celgene and BeiGene.



Yiwen Chen,
VP, Zensun


Chen Yiwen, PhD in Biomedicine from University of Macau, Member of American Chemical Society. He has more than ten years of experience in drug research and development, quality analysis, project management and business cooperation, and has published more than ten scientific research papers in international and domestic academic journals.

Corporate Speakers Confirmed



Betty Huang
BD Head, Bayer China

Betty Huang is experienced in business development with comprehensive finance, investment and healthcare industry knowledge, and led Bayer China/APAC BD&L team to accomplish multiple transactions with both global and domestic partners.



Luna Ji
Director of Search and Evaluation
Pacific BD&L Hub, MSD

She covers the waterfront of life science especially biotech opportunities, principally in the Greater China region (mainland, Hongkong, Taiwan) and Korea. She devotes her effort to lead the evaluation of asset for licensing-in and partnership opportunities in preclinical and pre POC (prove of concept) clinical stage for various therapeutic areas, in order to enrich global pipeline in R&D of MSD.



Xiaoning Guo
VP, R&D and CMO
SciClone Pharma

Dr. Guo obtained a bachelor's degree in chemistry from Nanjing University and a doctorate in pharmacology from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has more than 15-year experience in the pharmaceutical industry.



Puyang Liu
COO
Flometrica

Liu Puyang is the business director of innovation partnership, the technology transfer platform of Infinity group. He has rich experience in the business of early project incubation in Israel and technology transformation in China. He is good at investment and management in modern agriculture, new materials, medical devices and other fields. He has led a number of Sino-Israel joint venture projects and transformed more than ten patent achievements.



Darren Cunningham
CEO, Infection Biosciences

Darren Cunningham has 20 years senior management experience in life science companies. Darren spent 8 years at Amarin Corporation plc in a range of senior positions with responsibility covering business and corporate development.



Jim Wu
CEO, Ark Biosciences

Dr. Jim Wu is founder and CEO of Ark Biosciences. Dr. Wu has an extensive and successful pharma experience in which he contributed to development of antiviral, oncology, metabolic and CNS drugs. He was a senior scientist at Schering-Plough Research Institute, and director of preclinical and translational research at Valeant Pharmaceuticals.



Vishal Doshi
Chairman, CEO
AUM Biosciences

Vishal Doshi has extensive experience in structuring and managing risk sharing deals in various roles worth over \$1 billion USD. He also has done expensive clinical research across the pharmaceutical and CRO industry, spanning US, Europe and Asia. He used to hold senior business development and management roles at IQVIA, EPS International and ICON.



Sam Murphy
CEO, Salubris Bio

Sam is the CEO of Salubris Bio. He has worked at Salubris for over four years – joining the company as VP and Head of International Business Development, and subsequently taking an additional role as Chief Business Officer prior to becoming CEO. Sam worked for more than ten years in strategy consulting and transaction advisory services, most recently as a Senior Principal at IMS (now IQVIA).

Corporate Speakers Confirmed



Carlos Buesa
CEO, Oryzon Genomics

A founder of the Company in 2000, he has held the position of Chair of the Board of Directors since then. He earned his Ph.D. in Biochemistry from the University of Barcelona. He has been a member of the board of several biotechnology companies, such as: ONCNOSIS PHARMA AIE, NINFAS AIE, ORYCAMP-PROJECT AIE, GEADIG-PHARMA AIE, NEUROTEC PHARMA, S.L., PALOBIOFARMA, S.L.



Akira Jing Liu
BDD, AnHeart Therapeutics

Dr. Liu is BD Director of AnHeart Therapeutics. She supports AnHeart pipeline building, regional co-development and commercial partnership establishment and alliance management. Besides, she also supports AnHeart financing. Before AnHeart, Dr. Liu worked in a family office Qianzhan Investment.



Michaela Levin
Director Business Development
Constellation Pharmaceuticals

Dr. Michaela Levin brings over a decade of business development, licensing, IP and alliance management experience in biotech and academia. Prior to joining Constellation, Michaela was a Licensing Manager at Partners HealthCare Innovation, where she forged industry research alliances and delivered multiple transformational licensing deals.



Zigen WANG
BD Director
HUADONG MEDICINE

MBA, graduated in 2007 and joined Huadong medicine. Has been always engaged in investment management. Since 2017, has been focusing on business development, with comprehensive investment management, legal, financial skills and familiarity with the pharmaceutical industry.



Francesc Mitjans
CSO, LYKERA Biomed

Francesc Mitjans is PhD Biology (University of Barcelona). He holds 18 years in the Pharmaceutical Industry (Department Head at Merck-Serono) leading international projects of new anti-cancer drugs and biomarkers from discovery up to clinical trials. He has developed from concept idea up to phase II clinical trials a humanized mAb against alphav-integrins for cancer therapy.



Stefan Weber
CEO
Newron Pharmaceuticals SpA

Mr. Weber was appointed Chief Executive Officer and Executive Director of Newron in 2012. He had been Chief Financial Officer of the Company since April 2005. Stefan holds a master's degree in business management from FernUniversität Hagen (Diplom-Kaufmann). He has more than 30 years of industry experience in finance and general management.



Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics

Steven Yatomi-Clarke has combination of scientific and financial training, broad commercial and business background. He manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development.



Mei SU
CEO
Jiangsu Carephar Pharmaceutical

Dr. Su is committed to the research and development of novel P-CAB drug for gastric acid-related diseases, and highly selective new molecular entity. She has 25-year experience in early R&D, preclinical and clinical development. As the project leader, she brought 3 new molecular entities to clinical stage.

Corporate Speakers Confirmed



Yufeng Wang
BDD, AnHeart Therapeutics

Mr. Wang has more than 18 years work experience in big MNC HQ and emerging biotech companies in China and spent 12 years in pharmaceutical industry, with responsibility for Marketing, Portfolio Management, Business Development and Alliance Management.



Eric Halioua
CEO
PDC Line Phama

Serial entrepreneur that combines strong strategic, technological, managerial, fund-raising and deal-making experience. Eric has raised more than €130 million over the course of his career and has had numerous successes in the sale and initial public offering of biotechnology companies.



Jianmo Li
CEO, Konee

Dr. Jianmo Li graduated from the Department of Bioengineering and Mechanics at Imperial College London, his research focused on developing articular cartilage repair techniques. After graduation, he returned to China and founded a startup named Konee Co.,Ltd.



Apply to present @ ACCESS CHINA



To apply for a “Presenting Slot”, you simply need to submit the **application form** accessible via the link you can find below. Once approved by Forum Organizing Committee, you will be offered the chance to present at ACCESS CHINA Forum @JPM WEEK. Presenting slots will be given out on a **first come, first served** basis.

For Registration, please go to:

<https://biotechchina.org/register/>

ACCESS CHINA Online Partnering Day 3-Step Process



Step 1. Presentation Submission & Review
Company submits application form with partnering objectives (licensing, capital raising, M&A, etc).
ACCESS CHINA Committee will review the opportunity in the related therapeutic areas and accept the application.

Step 2. Online Presentation
YAFO Life Science banking team will help you to prepare and coordinate for the conference day.

Company will present either via recording presentation or live presentation (please let us know your preference in the application xls form). Presentation replay will be organized 7 days afterwards.

After the conference, YAFO will collect interests and feedbacks from Chinese investors and provide with “investor list names” the presenting company. (free of charge)

Step 3. Customized exposure & Deal Closing
YAFO will expose Company to a larger and customized list based on our investor base in related therapeutic area (for engaged clients only).

Facilitate the signing of LOI/Term Sheet, Due Diligence, and closing of the transaction.

JOIN US WHEN YOU ARE READY

For Global Biopharma Companies

No need to wait for months to spend time and money for a physical event in China. As ACCESS CHINA has several Online Partnering Day events through the year, you are welcome to join us when you are ready.

For Chinese Biopharma Companies

ACCESS CHINA has strong coverage of pharmaceutical and biotech companies from North America, Europe, MENA, Japan, Korea, and etc. This offers you an ideal channel to meet with potential out-licensing or commercial partners in different regions.



Live

+

Replay

LIVE DAY

During the live showcase held at ACCESS CHINA Online Partnering Day, presenters can discuss their pipeline, R&D activities, fundraising goals, and expectations from China market. Event audiences will come from 2,000+ BD Directors & Executives from biopharma companies and PE/VCs.

REPLAY DAY

For investors missing the live presentations, a replay-day will be arranged one week later. This will give the presenters even broader exposure.

Not just another conference, you have a strong banking team supporting you!

YAFO Life Science Banking Team



Sean Jiang, CFA
CEO & Founder

20+ years Wall Street banking & investment experience with Roth Capital, Xiangcai Securities, etc.. Former China GM of ISI Group (Evercore).



Fan Zheng
Managing Director
China Execution

Extensive involvement and expertise in 30+ global life science licensing & cross border financial transactions. Former analyst at Roth Capital.



Kun Tao, CFA
Partner
US Operations

20+ years of Wall Street experience in equity research and cross-border pharma licensing/investment with Roth Capital, Connective Capital, and Acorn.



Victor Ye
Partner
China Division

20+ years of pharmaceutical industry experience; Former Head of BD&AM in GSK China; Former Engineering Head, GE Healthcare.



William Yao
Partner
Asset In-licensing

30 years+ healthcare experience, including 7+ years in AstraZeneca China. Co-founder of Cyberpharm Investment & Sino-Octa; former doctor at Renji Hospital.



Andy Sun
Partner
Licensing

18 years experience in pharma R&D, BD & licensing, and investment in life science industry, including CASI Pharma, Tianjin Chase-sun Pharma, etc.



Steve Engen
Partner, US & Japan
YAFO-Renexes

20+ years of Japanese and US biopharma industry experience with Shire, Solasia Pharma, Mundipharma, etc., brought 10+ US pharma products to the Japanese market.



Dr. Mathias Schott
Director, Europe
YAFO-FCF

7+ years of European biotechnology and medtech capital raising & M&A industry experience. Mathias is also co-author of several LS capital markets publications.



Qi Li
China BD Director

Pharma industry analysis and investment banking (M&A, Licensing). 15+ Cross-border transactions experience.



Gian Dell Antonio
BD Manager
London Office

Pharma industry analysis and investment banking (M&A, Licensing). Former research analyst at PE Lab SDA Bocconi.



Wendi Xiang
Vice President

Cross border transaction analyst and fund administrator. BA, University of Nottingham; MA, University of Warwick.



Michelle Liu
Analyst

Extensive involvement in 5+ Cross-border transactions. BA, University of Oregon.



雅法全球医疗
YAFO Life Science

SPRING
春

May 15, 2020
Online

SUMMER
夏

July 31, 2020
Online

AUTUMN
秋

Sept. 25, 2020
Qingdao
BD Forum

WINTER
冬

Jan. 2021
San Francisco
@JPM

ACCESS CHINA FORUM 2020

*The Largest Corporate Access Event Between
China And Western Biopharma Industry*



America
9am - 12 pm



Asia
2 - 3 pm



Europe
3 - 5 pm



China
8 - 10 pm

Contact us



For Registration, please go to:

<https://biotochina.org/register/>

For applying roadshow slots, attendance, sponsoring, and media support. Please contact:

- Wendi Xiang, Vice President, wxiang@yafocapital.com; +86 137 3368 5995
- Gian Dell Antonio, BD Manager, gandrea@yafocapital.com; +44 7425 307 383

ORGANIZERS



CO-ORGANIZERS



MEDIA AND SUPPORT



ACCESS CHINA Past Events



ACCESS CHINA is a series of events that YAFO organizes each year, including East Meets West Mixing Dinner @ JPM, ACCESS CHINA BD Forum @ BIO International Convention, CHINA BD Forum (September each year), and ACCESS CHINA Online Partnering.

105
Companies

7000+
Views

1200+
Requests

300+
Assets



Previous Presenting Companies

American Companies



European Companies



Asian Companies



Greater China Companies

